Quantum Immunologics, Inc. Announces Clinical Study Collaboration With Florida Cancer Institute

TAMPA, FL--(Marketwire - September 27, 2010) -

Quantum Immunologics, Inc., a Tampa, FL-based company currently engaged in an FDA-authorized clinical study of its autologous dendritic cell immunotherapy for Stage IV breast cancer patients, is pleased to announce that it has completed a Clinical Study Agreement with Florida Cancer Institute-New Hope, a large oncology group with six clinical sites in the Tampa region. Under the Agreement, FCI-NH has agreed to act as an investigative site for the trial. As the sponsor of the study, Quantum also maintains two additional sites in Mobile, AL and Tampa. Five oncologists from FCI-NH have agreed to act as sub-investigators, including Dr. Gerald Robbins, the current president of the Florida Association of Clinical Oncology (FLASCO), a group dedicated to increasing the number of high quality cancer trials available in Florida.

Quantum’s CEO, Chuck Broes, expressed deep satisfaction with the new arrangement: “We’re very pleased that FCI-NH and its esteemed clinicians and researchers have agreed to become involved in our study. We’re very much looking forward to working with these physicians and their dedicated staff to finish the treatment portion of the study and to move forward to a larger phase of the trial.”

Florida Cancer Institute-New Hope is affiliated with U.S. Oncology, the nation’s largest network of community oncologists and cancer researchers, with over 400 affiliated sites of care, and more than 1,300 physicians.

About Quantum Immunologics
Quantum Immunologics is dedicated to the research, development and production of products and services that will promote unique, individualized immunologic cancer treatment and early detection technologies with a high rate of efficacy, minimal side effects and greatly reduced cost compared to current treatments.

Quantum Immunologics has received FDA authorization to apply its exclusively licensed immunotherapy technology in a Phase I/II human clinical study. QI’s Phase I/II clinical trial, which involves a cohort of 27 patients with advanced-stage metastatic breast cancer, is designed around the use of QI’s proprietary dendritic cell therapy, which employs the oncofetal antigen/immature laminin receptor protein (“OFA/iLRP”) to recruit the patient’s own immune system to target the cancer cells with the goal of improving patient survivability and quality of life.

Forward-Looking Statements
This press release contains “forward-looking statements” as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management’s current expectations and involve risks and uncertainties, which may cause results to differ materially from those set forth in the statements. The forward-looking statements may include, but are not limited to, statements regarding product development, product potential or financial performance. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Quantum Immunologics, Inc. undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.